中国临床药理学杂志2025，Vol.41Issue(4)：576-580,5.DOI:10.13699/j.cnki.1001-6821.2025.04.026
特泊替尼在非小细胞肺癌中的研究进展
Research progress of tepotinib in non-small cell lung cancer
摘要
Abstract
A common carcinogenic mechanism in non-small cell lung cancer(NSCLC)is a jump mutation in exon 14 of the mesenchymal epithelial transition factor(MET)gene,which is commonly present in NSCLC cases and accelerates cancer progression.Clinical studies have shown that tepotinib,as the first oral tyrosine kinase inhibitor targeting MET,exhibits significant efficacy in advanced NSCLC,with an overall response rate(ORR)of 44.7％and a median progression free survival(PFS)of 8.9 to 12.2 months.Although drug resistance appears within 6 to 12 months after treatment,combined treatment with epidermal growth factor receptor(EGFR)-tyrosine kinase inhibitors(TKIs)can overcome some of the resistance caused by EGFR mutations and MET expansion.In addition,tepotinib has good safety in different patient populations,with common adverse reactions including peripheral edema,nausea,and diarrhea.Tepotinib significantly prolongs the PFS of patients.In addition,other novel MET-TKI such as carbamatinib and sevotinib have also shown good efficacy in the treatment of MET mutant NSCLC.This article summarizes the pharmacological effects,resistance mechanisms,adverse reactions,and clinical application progress of terbotinib in NSCLC.关键词
特泊替尼/间质-上皮细胞转型因子激酶抑制药/药理作用/合成路线/临床评价/药物不良反应Key words
tepotinib/mesenchymal-epithelial transition factor kinase inhibitor/pharmacological effects/synthetic route/clinical evaluation/adverse drug reaction分类
医药卫生引用本文复制引用
沈继伟,吴霜,杨睿,王欣,张欣雨,多美颖,刘举..特泊替尼在非小细胞肺癌中的研究进展[J].中国临床药理学杂志,2025,41(4):576-580,5.基金项目
沈阳市自然科学基金资助项目(23-503-6-12) （23-503-6-12）
